Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of ...
As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate ...
CSL Seqirus has announced a strengthened partnership with the UK government that will see the UK become the first country in ...
The SAB brings together leading global experts with complementary expertise across Alzheimer’s disease biology, biomarkers, ...
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica ...
Imfinzi is approved in the US, EU, Japan, China and many other countries around the world as the standard-of-care treatment ...
Kondru joined the Emmes Group in 2024 and most recently served as CEO of Veridix, the company’s AI, technology, and data ...
Join Impetus Digital's pharma-exclusive webinar to discover how compliant AI tools and virtual workflows can elevate static ...
The two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases ...
At eight years of follow-up, results showed that Tagrisso continued to show an OS benefit, reducing the risk of death ...
Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator The Medicines and Healthcare products Regulatory Agency (MHRA) has approved KalVista ...
Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results